BridgeBio Pharma Inc (BBIO)

Oct 30, 2026

BridgeBio Pharma reported strong financial results for Q3 2026, with total revenues of $353.2 million, driven by acoramidis sales and a $75 million milestone from Bayer. The company is preparing for three significant product launches—BBP-418, infigratinib, and encaleret—all under priority review with the FDA. BridgeBio remains confident in its acoramidis franchise, projecting $4 billion in peak-year sales, and highlights compelling real-world evidence differentiating it from competitors.

Oct 28, 2026

BlackRock, Inc. has disclosed a 5.1% beneficial ownership stake in BridgeBio Pharma, Inc., totaling 9,892,226 shares of common stock. This information was reported in a Schedule 13G filing with the SEC on October 27, 2026, with the triggering event date being September 30, 2026. BlackRock holds sole voting power over 9,576,011 shares and sole dispositive power over all 9,892,226 shares, confirming the acquisition was in the ordinary course of business.